Page 7 - Resolution Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A earnings call for the period ending April 30, 2021.

Agilent to acquire Resolution Bioscience for $695 M Agilent to acquire Resolution Bioscience for $695 M 03 March 2021 | News Source credit: Shutterstock Agilent Technologies Inc has announced that it has entered into a definitive agreement to acquire Resolution Bioscience Inc, a leader in the development and commercialisation of next-generation sequencing (NGS)-based precision oncology solutions. The acquisition complements and expands Agilent’s capabilities in NGS-based cancer diagnostics and provides the company with innovative technology to further serve the needs of the fast-growing pr...

Agilent Revs up Precision Medicine Push with Planned Resolution Bioscience Acquisition March 3, 2021 [Source: Getty Images North America] In a planned acquisition aimed at expanding its next-generation sequencing (NGS)-based capabilities in cancer diagnostics, Agilent Technologies announced yesterday it has agreed to buy Resolution Bioscience for up to $695 million. Once rolled into the company, Resolution Bioscience’s liquid biopsy platform will complement Agilent’s existing tissue-based companion diagnostics business. In total, Agilent says the addressable market for these diagnostic t...

Search jobs 10-Feb-2021 Single Cell Genomics and Proteomics Market Trends, Growth, Industry Share, Size, Latest Innovation by Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Danaher, WATERS, Bio-Rad Laboratories “Global Single Cell Genomics and Proteomics Market–Industry Trends, Analysis and Forecast to 2027” New Research Report Added to Databridgemarketresearch. This report is provided with complete 350 pages,220 list of tables, 60 no of figures and also infographics. This Single Cell Genomics and Proteomics Market report gives ...

Dr. Emmanuel Fombu and Pek Lum Ph.D. Dr. Emmanuel Fombu is an internationally recognized authority on the convergence of digital technologies and healthcare. He is an award-winning and best-selling author, physician, Keynote speaker, investor, entrepreneur, and medical futurist with over 15 years of combined experience in science, research, and healthcare. Dr. Fombu did his clinical training at Emory-Crawford Long Hospital and holds an MBA from both Cornell University’s Johnson School of Business and Queen’s University’s Smith School of Business. He also earned a certification in Artifi...